These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33657264)

  • 1. Pediatric asthma control during the COVID-19 pandemic.
    Ferraro VA; Zamunaro A; Spaggiari S; Di Riso D; Zanconato S; Carraro S
    Immun Inflamm Dis; 2021 Jun; 9(2):561-568. PubMed ID: 33657264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of biological therapy in children and adolescents with severe asthma during the COVID-19 pandemic: a case series.
    Votto M; Santi V; Bajeli M; De Filippo M; Deidda E; De Stefano E; Dianin F; Raviola C; Silvi C; Marseglia GL; Licari A
    Acta Biomed; 2022 Jun; 93(S3):e2022053. PubMed ID: 35666117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up.
    Folqué MM; Lozano J; Riggioni C; Piquer M; Álvaro M; Machinena A; Giner MT; Domínguez O; Jiménez-Feijoo RM; Dias da Costa M; Plaza AM
    Allergol Immunopathol (Madr); 2019; 47(4):336-341. PubMed ID: 30509559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 in a patient with severe asthma treated with Omalizumab.
    Lommatzsch M; Stoll P; Virchow JC
    Allergy; 2020 Oct; 75(10):2705-2708. PubMed ID: 32544254
    [No Abstract]   [Full Text] [Related]  

  • 5. The course of COVID-19 in patients with severe asthma receiving biological treatment.
    Tuncay G; Cakmak ME; Can Bostan O; Kaya SB; Damadoglu E; Karakaya G; Kalyoncu AF
    J Asthma; 2022 Nov; 59(11):2174-2180. PubMed ID: 34669544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric asthma symptom control during lockdown for the COVID-19 pandemic in Spring 2020: A prospective community-based study in Cyprus and Greece.
    Kouis P; Michaelidou E; Kinni P; Michanikou A; Anagnostopoulou P; Dimitriou H; Karanicolas K; Matthaiou AM; Achilleos S; Papatheodorou SI; Koutrakis P; Middleton N; Galanakis E; Yiallouros PK
    Pediatr Pulmonol; 2022 Feb; 57(2):386-394. PubMed ID: 34818465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab management beyond clinical trials: the added value of a network model.
    Caminati M; Senna G; Chieco Bianchi F; Marchi MR; Vianello A; Micheletto C; Pomari C; Tognella S; Savoia F; Mirisola V; Rossi A;
    Pulm Pharmacol Ther; 2014 Oct; 29(1):74-9. PubMed ID: 24508951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lockdown effects on a pediatric obese population in the COVID-19 era.
    Valenzise M; D'Amico F; Cucinotta U; Lugarà C; Zirilli G; Zema A; Wasniewska M; Pajno GB
    Ital J Pediatr; 2021 Oct; 47(1):209. PubMed ID: 34663397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma.
    Har D; Lee MJ
    Allergy Asthma Proc; 2019 Jan; 40(1):35-40. PubMed ID: 30582494
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study.
    Pitrez PM; de Souza RG; Roncada C; Heinzmann-Filho JP; Santos G; Pinto LA; Jones MH; Stein RT
    Pediatr Pulmonol; 2017 Nov; 52(11):1408-1413. PubMed ID: 29027379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia].
    Morales-Múnera O; Pedraza Á; Niño-Serna L
    Rev Alerg Mex; 2018; 65(3):222-232. PubMed ID: 30176200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of COVID-19 lockdown on children with recurrent wheezing and asthma in Spain.
    Daoud Pérez Z; Rázquin Arias M; López-Escobar A; Díaz-Conradi A; Arce A; Ruggeri N; Romero Blanco I; Díaz-Delgado B; Ventura Wichner PS
    J Paediatr Child Health; 2022 Sep; 58(9):1635-1641. PubMed ID: 35748401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy.
    Novelli F; Latorre M; Vergura L; Caiaffa MF; Camiciottoli G; Guarnieri G; Matucci A; Macchia L; Vianello A; Vultaggio A; Celi A; Cazzola M; Paggiaro P;
    Pulm Pharmacol Ther; 2015 Apr; 31():123-9. PubMed ID: 25281265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
    Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
    Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-life long-term omalizumab therapy in children with severe allergic asthma.
    Deschildre A; Marguet C; Langlois C; Pin I; Rittié JL; Derelle J; Abou Taam R; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2015 Sep; 46(3):856-9. PubMed ID: 26022964
    [No Abstract]   [Full Text] [Related]  

  • 19. Prescriptive adherence to GINA guidelines and asthma control: An Italian cross sectional study in general practice.
    Baldacci S; Simoni M; Maio S; Angino A; Martini F; Sarno G; Cerrai S; Silvi P; Pala AP; Bresciani M; Paggiaro P; Viegi G;
    Respir Med; 2019 Jan; 146():10-17. PubMed ID: 30665506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Patients in the IDEAL cohort: A snapshot of severe asthma in France].
    Taillé C; Pison C; Nocent C; Devouassoux G; Prud'homme A; Gruber A; Gunsoy N; Albers F
    Rev Mal Respir; 2019 Feb; 36(2):179-190. PubMed ID: 30429093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.